Louis Garguilo
ARTICLES BY LOUIS
-
8/12/2020
Of 367 production plants BASF operates worldwide, six are Verbund sites. Those six produce more than 50% of all BASF volumes. A CEO of a U.S.-based CDMO thinks Verbund is the kind of thinking needed at drug development and manufacturing facilities in this country.
-
8/10/2020
According to a new industry report on global bioprocessing, U.S.-based CDMOs are in a strong position. Is it so strong that capacity becomes an issue for readers relying on these service providers for new drug programs?
-
8/5/2020
CDMO search and evaluation are at the core of drug development and manufacturing outsourcing. Google, the company that built an empire on returning high-quality search results, makes a case for E-A-Ting your CDMO partners.
-
7/29/2020
Jonathan Freeman of Anthos Therapeutics says it’s “economic Darwinism” come visit the pharma world. Karen Fallen of Lonza admits it's “potentially highly complex.” Both believe today it's a reproducible “value-creation model.”
-
7/22/2020
Fabian Stocker of SCHOTT has a soothing mathematical calculation to reduce our COVID-19 "vial shortage anxieties.” It also informs every drug developer to continue full speed ahead: There are vials for you as well.
-
7/16/2020
Arena Pharmaceuticals focuses on making administration of the drug dosage form as easy as possible for the patient. “Within that simplicity,” says EVP Doug Bakan, “innovation takes place.” With help from some well-chosen CDMOs.
-
7/14/2020
Today the mention of “vials” leads to questions of supplies for COVID-19 vaccines. But thoughts of vials normally pertain to your own drug develop program needs. For advice, I asked one of the biggest glass producers in the world.
-
7/9/2020
We are refocused on drug development and manufacture in the U.S. But where in this big country makes the most dollars and sense for locating operations? One place drug manufacturing has traditionally flourished is Puerto Rico.
-
6/29/2020
“But we forgot our people,” says an introspective biopharma executive, regarding pre-coronavirus risk assessments. Here's a look at what did and might have happened, and thoughts for the future of outsourcing.
-
6/22/2020
There's a new cell-and-gene service organization out there: the non-CDMO. Here's who they are, an analysis of why they're different, and a look at how they can help you.